Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATG-101
- Development stage
- Unknown
- Lead developer
- Antengene
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ATG-101 is a novel investigational bispecific antibody that targets both programmed death-ligand 1 (PD-L1) and 4-1BB (CD137). It is designed to block the immunosuppressive interaction between PD-1 and PD-L1, while conditionally stimulating 4-1BB, a co-stimulatory receptor on T cells. This dual mechanism aims to enhance anti-tumor immune responses by activating exhausted T cells in the tumor microenvironment, potentially improving efficacy and safety compared to previous 4-1BB agonists. The drug is being developed primarily for cancer indications, including pancreatic cancer[2][3][5][6].
- Other names
- PD-L1/4-1BB bispecific antibody
02
Targets
TNFRSF9 (CD137 extracellular domain)FCGRT (Neonatal crystallizable fragment receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on ATG-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATG-101.